Please login to the form below

Not currently logged in
Email:
Password:

CGRP

This page shows the latest CGRP news and features for those working in and with pharma, biotech and healthcare.

New efficacy data boosts Aimovig’s migraine market lead

New efficacy data boosts Aimovig’s migraine market lead

The results from the STRIVE trial are good news for Novartis and its co-marketer Amgen, who have established Aimovig (erenumab) as the leader in the new class of CGRP inhibitor ... These results expand the potential scope of Aimovig’s use, and will

Latest news

  • AbbVie CEO Gonzalez defends Allergan takeover AbbVie CEO Gonzalez defends Allergan takeover

    For AbbVie, Allergan’s most interesting programmes are a clutch central nervous system (CNS) candidates including antidepressant Vraylar (cariprazine) – which it says has blockbuster potential – as well as oral CGRP inhibitors

  • Lilly claims cluster headache first for CGRP drug Emgality Lilly claims cluster headache first for CGRP drug Emgality

    Competition fierce in new class. Eli Lilly has pushed its nose in front of its rivals in the CGRP inhibitor market with the first FDA approval of a drug in the ... It’s not only the first of the new CGRP inhibitor class to be approved for the condition,

  • Pricing pressures peg back Lilly’s growth products Pricing pressures peg back Lilly’s growth products

    Lilly has other new medicines rolling out to help it manage the Cialis patent cliff, and third-to-market CGRP inhibitor for migraine – Emgality (galcanezumab) - added $14m in the quarter, overtaking

  • Novartis and Amgen come to blows over migraine partnership Novartis and Amgen come to blows over migraine partnership

    Amgen has filed a lawsuit accusing Novartis of breaching their partnership for CGRP inhibitor Aimovig (erenumab) and seeking to terminate their 2015 contract, which gives Novartis co-marketing rights in the ... Aimovig was approved by the FDA last year

  • Teva’s migraine injection approved in Europe Teva’s migraine injection approved in Europe

    Third anti-CGRP treatment to hit the market. The European Medicines Agency has approved Teva’s migraine prevention drug Ajovy, adding a third competitor to a fast-expanding market. ... The FDA also recently accepted an NDA from Botox developer Allergan,

More from news
Approximately 5 fully matching, plus 33 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Licence. 217. Teva Pharmaceuticals/ Alder Biopharmaceuticals. Patents covering anti-calcitonin gene-related peptide (CGRP) antibodies and methods - eptinezumab (p3). † ... licence agreement in January with respect to calcitonin gene-related peptide

  • The good, the bad and the ugly The good, the bad and the ugly

    Three CGRP monoclonal antibodies will launch in the US for migraine in 2018 - with a fourth anticipated in 2019.

  • Deal Watch November 2015 Deal Watch November 2015

    455. Heptares. Teva. Licence drug-discovery agreement. Small molecule calcitonin gene-related peptide (CGRP) antagonists for migraine.

  • Pharma deals in July 2015 Pharma deals in July 2015

    related peptide (CGRP) receptor antagonist programme with the lead product at the end of phase II for treatment of migraine. ... 293. Merck / Allergan. Acquisition of R&D. Oral CGRP compounds (lead Phase 2) for migraine.

  • Deal Watch table for June 2014 Deal Watch table for June 2014

    3, 850. Labrys Biologics/ Teva. Company acquisition. Includes Labrys' p2b anti-CGRP mAb for treatment of episodic migraine.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics